

Preprints are preliminary reports that have not undergone peer review. They should not be considered conclusive, used to inform clinical practice, or referenced by the media as validated information.

Bacteroides ovatus alleviates dysbiotic microbiotainduced intestinal graft-versus-host disease

Robert Jenq (rrjenq@mdanderson.org)

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center https://orcid.org/0000-0002-5434-439X

Eiko Hayase

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Tomo Hayase

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Akash Mukherjee

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

Stuart Stinson

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

Mohamed Jamal

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Miriam Ortega

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Christopher Sanchez

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Saira Ahmed

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Jennifer Karmouch

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Chia-Chi Chang

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Ivonne Flores

The University of Texas MD Anderson Cancer Center

Lauren McDaniel

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Alexandria Brown

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Rawan El-Himri

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Valerie Chapa

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Lin Tan

University of Texas MD Anderson Cancer Center

Bao Tran

Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center

Dung Pham

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Taylor Halsey

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Yimei Jin

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Wen-Bin Tsai

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Rishika Prasad

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Israel Glover

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Nadim Ajami

UT MD Anderson Cancer Center

Jennifer Wargo

MD Anderson https://orcid.org/0000-0003-3438-7576

Samuel Shelburne

Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center

Pablo Okhuysen

The University of Texas MD Anderson Cancer Center https://orcid.org/0000-0002-1596-3411

Chen Liu

Yale University School of Medicine

Stephanie Fowler

Department of Molecular Virology and Microbiology, Baylor College of Medicine

Margaret Conner

Department of Molecular Virology and Microbiology, Baylor College of Medicine

Christine Peterson

University of Texas https://orcid.org/0000-0003-3316-0468

Gabriela Rondon

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

Jeffrey J Molldrem

M. D. Anderson Cancer Center https://orcid.org/0000-0003-1196-1715

Richard Champlin

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

Elizabeth Shpall

MD Anderson Cancer Center

Philip Lorenzi

the university of texas md anderson https://orcid.org/0000-0003-0385-7774

Rohtesh Mehta

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

Eric Martens

University of Michigan-Ann Arbor https://orcid.org/0000-0001-6681-2990

Amin Alousi

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center

Biological Sciences - Article

Keywords: Bacteroides ovatus, Bacteroides thetaiotaomicron, allogeneic hematopoietic stem cell transplantation, graft-versus-host disease, carbapenem, intestinal microbiome, mucus layer, xylose, polysaccharides, polysaccharide utilization loci

Posted Date: January 31st, 2023

DOI: https://doi.org/10.21203/rs.3.rs-2460097/v1

License: (a) This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Additional Declarations: Yes there is potential Competing Interest. R.R.J. has served as a consultant or advisory board member for Merck, Microbiome DX, Karius, MaaT Pharma, LISCure, Seres, Kaleido, and Prolacta and has received patent license fee or stock options from Seres and Kaleido. E.J.S. has served as a consultant or advisory board member for Adaptimmune, Axio, Navan, Fibroblasts and FibroBiologics, NY Blood Center, and Celaid Therapeutics and has received patent license fee from Takeda and Affimed. E.H., M.A.J., J.L.K., and R.R.J. are inventors on a patent application by The University of Texas MD Anderson Cancer Center supported by results of the current study entitled, "Methods and Compositions for Treating Cancer therapy-induced Neutropenic Fever and/or GVHD."

Bacteroides ovatus alleviates dysbiotic microbiota-induced intestinal graftversus-host disease

3

4 Eiko Hayase¹, Tomo Hayase^{1*}, Akash Mukherjee², Stuart C. Stinson², Mohamed A. Jamal¹, 5 Miriam R. Ortega¹, Christopher A. Sanchez¹, Saira S. Ahmed¹, Jennifer L. Karmouch¹, Chia-Chi Chang¹, Ivonne I. Flores¹, Lauren K. McDaniel¹, Alexandria N. Brown¹, Rawan K. El-Himri¹, 6 Valerie A. Chapa¹, Lin Tan³, Bao Q. Tran³, Dung Pham¹, Taylor M. Halsey¹, Yimei Jin¹, Wen-7 Bin Tsai¹, Rishika Prasad¹, Israel K. Glover¹, Nadim J. Ajami¹, Jennifer A. Wargo¹, Samuel 8 9 Shelburne^{1, 4}, Pablo C. Okhuysen⁴, Chen Liu⁵, Stephanie W. Fowler^{6, 7}, Margaret E. Conner⁶, 10 Christine B. Peterson⁸, Gabriela Rondon², Jeffrey J. Molldrem², Richard E. Champlin², Elizabeth J. Shpall², Philip L. Lorenzi³, Rohtesh S. Mehta^{2#}, Eric C. Martens^{9#}, Amin M. Alousi^{2#}, Robert 11 R. Jenq^{1, 2, 10#}* 12 13

14

15 Affiliations:

- ¹Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center,
 Houston, Texas 77054, USA
- ²Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD
 Anderson Cancer Center, Houston, Texas 77030, USA
- ³Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The
 University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA
- ⁴Department of Infectious Diseases, Infection Control and Employee Health, The University
 of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
- ⁵Department of Pathology, Yale School of Medicine, New Haven, Connecticut 06520, USA
- ⁶Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston,
 TX 77030, USA.
- ⁷Center for Comparative Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
- ⁸Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston,
 Texas 77030, USA
- ⁹Department of Microbiology & Immunology, University of Michigan Medical School, Ann
 Arbor, Michigan 48109, USA
- 32 ¹⁰CPRIT Scholar in Cancer Research, Houston, Texas, USA
- [#]These authors contributed equally.
- 34 *Correspondence: <u>RRJenq@mdanderson.org</u> (R.R.J.), <u>THayase@mdanderson.org</u> (T.H.)
- 35 36

1 Abstract

2 Acute gastrointestinal intestinal GVHD (aGI-GVHD) is a serious complication of allogeneic 3 hematopoietic stem cell transplantation, and the intestinal microbiota is known to impact on its 4 severity. However, an association between treatment response of aGI-GVHD and the intestinal 5 microbiota has not been well-studied. In a cohort of patients with aGI-GVHD (n=37), we found that non-response to standard therapy with corticosteroids was associated with prior treatment with 6 7 carbapenem antibiotics and loss of Bacteroides ovatus from the microbiome. In a mouse model of 8 carbapenem-aggravated GVHD, introducing Bacteroides ovatus reduced severity of GVHD and 9 improved survival. *Bacteroides ovatus* reduced degradation of colonic mucus by another intestinal 10 commensal, Bacteroides thetaiotaomicron, via its ability to metabolize dietary polysaccharides 11 into monosaccharides, which then inhibit mucus degradation by Bacteroides thetaiotaomicron and 12 reduce GVHD-related mortality.

13

14 Keywords

Bacteroides ovatus, Bacteroides thetaiotaomicron, allogeneic hematopoietic stem cell
 transplantation, graft-versus-host disease, carbapenem, intestinal microbiome, mucus layer, xylose,
 polysaccharides, polysaccharide utilization loci.

Introduction

2 Graft-versus-host disease (GVHD) is a common complication in patients undergoing 3 allogeneic hematopoietic stem cell transplantation (allo-HSCT) and occurs when donor T cells 4 recognize the patient's tissues as foreign. The intestine is often targeted, and severe acute 5 gastrointestinal GVHD (aGI-GVHD) tends to have a poor prognosis. Approximately half of aGI-GVHD cases do not respond to first-line steroid therapy, leading to a high risk for severe 6 7 complications and reduced overall survival^{1,2}. Novel immune suppression strategies to treat 8 steroid-refractory GVHD have been established, including Janus kinase 1/2 (JAK1/2) inhibitors, 9 with demonstrated clinical efficacy, though not all patients will respond 3,4 . The intestinal microbiota is an important modulator of the host immune system^{5,6} and 10 11 modulates the pathophysiology of GVHD⁷. Patients undergoing allo-HSCT are at high risk for

perturbations in the intestinal microbiota resulting from a number of factors; chief amongst them exposure to antibiotics for prevention and treatment of bacterial infections post-transplant. Broadspectrum antibiotics such as carbapenems have been reported to increase the incidence of aGI-GVHD ⁸⁻¹¹. Recently, fecal microbiota transplantation has been shown to result in improvement in GVHD in steroid-refractory patients¹²⁻¹⁴, suggesting that the intestinal microbiota can modulate aGI-GVHD treatment responsiveness. It remains unclear, however, how intestinal microbial composition can modulate treatment response of aGI-GVHD.

In this study, we aimed to evaluate for an impact of intestinal microbiota at the onset of aGI-GVHD on GVHD severity. Our retrospective analysis of 37 aGI-GVHD patients showed that steroid-refractory GVHD was significantly associated with higher clinical stages and histological grades of aGI-GVHD at the onset of aGI-GVHD and prior treatment with carbapenem-class antibiotics such as meropenem before onset of aGI-GVHD was significantly associated with steroid-refractory GVHD. An examination of the intestinal microbiome collected from aGI-

1 GVHD patients at the onset of aGI-GVHD revealed that steroid-refractory patients showed greater 2 dysbiosis than responsive patients and high abundances of *Bacteroides ovatus* were significantly 3 associated with improved response to steroid therapy in aGI-GVHD patients.

4 We recently found that in a murine GVHD model, treatment with meropenem, a commonly 5 used carbapenem in allo-HSCT patients, expanded a mucus-degrading bacterial species, 6 Bacteroides thetaiotaomicron (B. theta), and aggravated colonic GVHD¹⁵. Using this model, we 7 evaluated for the impact of *B. ovatus* on GVHD severity in mice with meropenem-aggravated 8 colonic GVHD. Consistent with the clinical findings, we found that introduction of B. ovatus 9 improved survival of mice with meropenem-aggravated colonic GVHD. B. ovatus also inhibited 10 the expansion and mucus-degrading functionality of *B. theta*. Meropenem altered not only the 11 microbiome composition but also the intestinal environment, including the levels of carbohydrates, 12 increasing mucus-degrading functionality by B. theta. Thus, altered functions of intestinal 13 microbes due to changes of metabolic substrates in the colonic lumen can strongly modulate GVHD severity. B. ovatus has been reported to have a different spectrum of polysaccharide-14 15 degrading functions compared to that of *B*. $theta^{16}$. Importantly, we confirmed via in vitro assay 16 that B. ovatus unlike B. theta did not show mucus-degrading functionality. Indeed, medium 17 containing xylose-comprising polysaccharides and conditioned by *B. ovatus* could suppress the 18 mucus-degrading functionality of B. theta in vitro. The ability of B. ovatus to degrade xylose-19 comprising polysaccharides and produce abundant monosaccharides including xylose in the 20 colonic lumen may play a key role in improving the intestinal metabolic environment in allo-HSCT 21 and prevent expansion of *B. theta*, leading to favorable outcomes of aGI-GVHD.

- 22
- 23
- 24

Results

Bacteroides-enriched microbiome was associated with favorable treatment response of aGI-

2 GVHD in allo-HSCT patients

To investigate the potential impact of intestinal microbiome composition on aGI-GVHD treatment response, we retrospectively studied patients at MD Anderson Cancer Center who developed aGI-GVHD in the setting of allo-HSCT from 2017 to 2019. A total of 37 patients were diagnosed with aGI-GVHD (Supplementary Table 1): 28 with classic aGI-GVHD and 9 with lateonset aGI-GVHD, by National Institutes of Health consensus criteria¹⁷. We determined treatment response as previously reported¹⁸. All patients received initial therapy with methylprednisolone or prednisone at 2 mg/kg/day followed by tapering per institutional guidelines.

10 An examination of the microbiome composition of the stool samples using 16S rRNA gene 11 sequencing revealed that our aGI-GVHD cohort showed a significantly distinct intestinal 12 microbiome at the onset of aGI-GVHD from that of healthy volunteers, visualized with principal 13 coordinates analysis (PCoA) and tested using permutational multivariate analysis of variance (PERMANOVA) (Extended Data Fig. 1a). In particular, aGI-GVHD patients showed significantly 14 15 higher abundance of the genus *Enterococcus* and reductions in the genera *Prevotella* and 16 Faecalibacterium (Extended Data Fig. 1b). These results were consistent with previous reports 17 identifying Escherichia coli and the genus Enterococcus as bacteria that can aggravate GVHD severity^{19,20}. 18

We next sought to identify naturally-occurring subsets within aGI-GVHD patients based on differences in microbiome composition. We classified aGI-GVHD patients using hierarchical clustering of weighted UniFrac beta diversity measures and identified 2 distinct groups, with 9 patients in cluster 1 and 28 patients in cluster 2 (Fig. 1a, b). Other than gender (cluster 1 included a significantly higher proportion of male patients; p = 0.01; Supplementary Table 2), no clinical transplant characteristics were significantly different between clusters 1 and 2. Interestingly, cluster 1 showed significantly less dysbiosis, as measured by weighted UniFrac from the microbiome of healthy volunteers (Fig. 1c, d). We also found that cluster 1 included a significantly higher proportion of steroid-responsive GVHD patients than cluster 2 (Fig. 1e, f). Performing differential abundance analysis on clusters 1 and 2, we found that cluster 1 was primarily characterized by increased abundance of the genus *Bacteroides* (Fig. 1g). Overall, these findings suggested that the composition of the intestinal microbiome may be associated with treatment response of aGI-GVHD.

8 We then investigated whether the composition of the intestinal microbiome at the onset of 9 aGI-GVHD was different between patients who would later be steroid-responsive or steroid-10 refractory. Our aGI-GVHD patient cohort included 20 patients whose aGI-GVHD was steroid-11 responsive and 17 patients whose aGI-GVHD was steroid-refractory. Other than age (refractory 12 cases were in significantly younger patients; p = 0.0002; Supplementary Table 3), no clinical 13 transplant characteristics were significantly different between responsive and refractory cases. The 14 time from allo-HSCT until the onset of aGI-GVHD was a median of 31.5 days (range, 14-367 15 days) in steroid-responsive patients and 42 days (13–257 days) in steroid-refractory patients.

16 We found that steroid-responsive patients showed significantly higher microbial alpha 17 diversity than steroid-refractory patients, but that this diversity was still lower than that of healthy 18 volunteers (Fig. 2a). Using PCoA with PERMANOVA testing, we found that the intestinal 19 microbiome was significantly different between steroid-responsive and steroid-refractory patients 20 (Fig. 2b) and that steroid-refractory patients showed greater dysbiosis than responsive patients, as 21 measured by their weighted UniFrac differences from the microbiome of healthy volunteers (Fig. 22 2b, c). We evaluated the bacterial taxa that were differentially abundant and found that steroid-23 refractory patients had reductions in the genera *Bacteroides* and *UBA1819* and higher abundances 24 of the genera Citrobacter, Streptococcus, Staphylococcus, and Enterobacter (Fig. 2d, e and

Extended Data Fig. 1c). Overall, these results suggested that alterations of the composition of the intestinal microbiome at clinical presentation of aGI-GVHD were associated with poor response to therapy.

- 4
- 5 No prior treatment with carbapenems and higher abundances of *Bacteroides ovatus* were 6 significantly associated with favorable outcomes of aGI-GVHD

7 Allo-HSCT patients are often treated with broad-spectrum antibiotics for febrile 8 neutropenia and other infections that arise before as well as after hematopoietic engraftment. These 9 antibiotics, however, can cause by stander damage to intestinal commensals that are critical for 10 maintaining intestinal homeostasis. Indeed, exposure to broad-spectrum antibiotics such as carbapenems has been linked to an increased incidence of aGI-GVHD⁸⁻¹¹. We examined patient 11 12 antibiotic treatment histories during the period from allo-HSCT to the onset of aGI-GVHD and 13 looked for associations with steroid response for GVHD (Fig. 3a). Steroid-refractory patients had significantly higher prior treatment with carbapenems but not quinolone, cephalosporin, or 14 15 intravenous vancomycin (Fig. 3b). Together, these results indicated that antibiotic-mediated 16 microbiome disruption could be an important determinant of response of GVHD to therapy.

17 To identify specific species of *Bacteroides* potentially associated with steroid response for 18 aGI-GVHD, we performed whole-genome sequencing on only 23 fecal samples which had 19 remained available genomic DNA or stool. In samples from 23 patients, including 11 steroid-20 responsive patients and 12 steroid-refractory patients, abundances of *B. ovatus* were significantly 21 increased in steroid-responsive patients (Fig. 3c). Analysis of abundances of individual 22 Bacteroides-derived genes demonstrated that Bacteroides from steroid-responsive patients showed 23 significantly distinct gene contents from that of *Bacteroides* from steroid-refractory patients using 24 PCoA with PERMANOVA testing (Fig. 3d). Evaluation of genetic pathways from Bacteroides

1 demonstrated that multiple genetic pathways of *Bacteroides* were significantly associated with 2 steroid-responsive patients but none of them in steroid-refractory patients. Interestingly, the top 50 3 pathways with significantly increased abundances in steroid-responsive patients, including the 4 pathways related with amino acid degradation and carbohydrate biosynthesis/degradation, 5 belonged to B. ovatus (Fig. 3e, f), indicating that B. ovatus is particularly associated with steroidresponsive GVHD in patients. In summary, results of 16S rRNA and whole-genome sequencing 6 7 of patient fecal samples at the onset of aGI-GVHD implicated a potential beneficial effect of B. 8 ovatus, which we further examined in a murine GVHD model.

9

10

B. ovatus suppressed meropenem-aggravated colonic GVHD in a murine GVHD model

To investigate whether *B. ovatus* influences GVHD outcomes in a murine GVHD model, we isolated *B. ovatus* from the stool of a healthy volunteer and named as MDA-HVS BO001. We assembled the complete genome of MDA-HVS BO001 and confirmed that it was a strain of *B. ovatus*, with 99.4% of the genomic identity of the ATCC strain of *B. ovatus* (ATCC 8483) (Extended Data Fig. 2a). Hereafter, we refer to our isolated *B. ovatus*, MDA-HVS BO001, as *B. ovatus*.

17 As exposure of carbapenems prior to aGI-GVHD onset was significantly associated with 18 the development of steroid-refractory GVHD, we used a meropenem-aggravated GVHD murine 19 model, previously described¹⁵, to determine the impact of *B. ovatus* on GVHD severity. Briefly, 20 lethally irradiated B6D2F1 (H- $2^{b/d}$) mice were intravenously injected with 5×10⁶ bone marrow cells and 5×10⁶ splenocytes from major histocompatibility complex (MHC)-mismatched B6 (H-21 22 2^{b}) mice on day 0. Meropenem was administered to the allo-HSCT recipient mice in their drinking 23 water on days 3 to 15 relative to allo-HSCT (Fig. 4a). We previously showed that allo-HSCT mice 24 treated with meropenem demonstrated aggravated colonic GVHD in association with loss of the

1 class Clostridia and expansion of Bacteroides thetaiotaomicron (B. theta) compared to those 2 untreated with meropenem. B. theta is a species of mucus-degrading bacteria that commonly colonizes the intestinal tract of both mice and humans 21 . In this model, expansion of *B*. theta 3 4 induces thinning of the colonic mucus layer and increases bacterial translocation, leading to 5 aggravated colonic GVHD. To compare mucus-degrading functionality between *B. ovatus* and *B.* 6 theta, we quantified degradation of mucin-derived carbohydrates in vitro using a periodic acid-7 Schiff (PAS)-based colorimetric assay (Extended Data Fig. 2b). As expected, B. theta displayed 8 degradation of mucin-derived carbohydrates, whereas *B. ovatus* did not (Extended Data Fig. 2c), 9 suggesting that *B. ovatus* has less potential to induce mucus-degrading bacteria-related aggravated 10 GVHD.

11 Next, to study the effects of *B*. ovatus on GVHD severity, we orally inoculated 2×10^7 12 colony-forming units of *B. ovatus* into meropenem-treated allo-HSCT recipient mice from days 13 16 to 18 and monitored GVHD severity and survival (Fig. 4a). Interestingly, we found that meropenem-treated mice that received *B. ovatus* showed significantly improved survival (Fig. 4b). 14 15 However, the favorable effects of *B. ovatus* were not seen in allo-HSCT mice not treated with 16 meropenem (Extended Data Fig. 3a, b), suggesting that B. ovatus can mitigate the severity of aGI-17 GVHD only in the context of disrupted microbiota. This finding, together with the finding that 18 expanded B. theta after meropenem treatment was associated with aggravated colonic GVHD, 19 indicated that different Bacteroides species, which are quite heterogeneous in their metabolic 20 functions, can mediate distinct and even opposing effects on aGI-GVHD^{22,23}. We hypothesized 21 that B. ovatus mitigate GVHD severity via their functionality for maintaining intestinal 22 homeostasis, which was supported by that *B. ovatus*-derived pathways were significantly 23 associated with steroid response in our whole-genome sequencing analysis.

1	To elucidate the mechanisms by which B. ovatus mitigated meropenem-aggravated colonic
2	GVHD, we examined the abundance and functionality of <i>B</i> . <i>theta</i> in both meropenem-treated and
3	untreated allo-HSCT mice with or without introduction of <i>B. ovatus</i> . Introduction of <i>B. ovatus</i> did
4	not alter bacterial density quantified by 16S rRNA gene quantitative polymerase chain reaction
5	(qPCR), or alpha diversity quantified using the Shannon index, in stool collected on day 21 in
6	meropenem-treated mice or in control allo-HSCT mice untreated with meropenem (Fig. 4c, d and
7	Extended Data Fig. 3c, d). Interestingly, expansion of B. theta induced by meropenem was
8	significantly suppressed by administration of <i>B. ovatus</i> in meropenem-treated mice (Fig. 4e, f).
9	Consistent with this, the thickness of the colonic mucus layer was significantly increased in
10	meropenem-treated mice that received B. ovatus compared to those without B. ovatus (Fig. 4g, h).
11	On the other hand, meropenem-untreated allo-HSCT mice showed no significant effects of
12	administration of B. ovatus on relative abundance of B. theta or colonic mucus layer thickness
13	(Extended Data Fig. 3e-h). These data suggested that <i>B. ovatus</i> suppresses the expansion of <i>B</i> .
14	theta in mice under certain conditions, such as following meropenem treatment, but otherwise does
15	not impact substantially on <i>B. theta</i> .
16	
17	
18	Introducing B. ovatus suppressed mucus-degrading functionality by B. theta in a murine
19	GVHD model
20	On the basis of our previous finding that meropenem treatment led to changes in
21	carbohydrate levels and mucus-degrading functionality of <i>B. theta</i> in our murine GVHD model ¹⁵ ,
22	we hypothesized that <i>B. ovatus</i> introduction could be impact the carbohydrate environment and <i>B</i> .
23	theta gene expression. We began with investigating the effect of B. ovatus on B. theta gene

24 expression in meropenem-treated allo-HSCT mice, by performing microbial RNA sequencing of

1 stool samples. We examined RNA reads from *B. theta* and annotated these using the polysaccharide utilization loci (PULs) DataBase²⁴. We found that administration of *B. ovatus* in 2 3 meropenem-treated allo-HSCT mice led to downregulation in B. theta of many PULs that 4 contribute to degradation of mucin O-glycans, including PULs 12, 16, 78, 81, and parts of 14 (Fig. 5 5a and Extended Data Fig. 4a). In contrast, in meropenem-untreated mice, administration of B. ovatus did not result in downregulation of any of these PULs by B. theta which generally showed 6 7 few transcriptomic changes, which was supported by that *B. theta* in meropenem-untreated mice 8 did not increase the mucus-degrading functionality in our prior study ¹⁵ (Extended Data Fig. 4b). 9 These results suggested that B. ovatus not only suppressed expansion of B. theta relative 10 abundances, but also produced downregulation of mucus-degrading functionality by B. theta in 11 meropenem-treated allo-HSCT mice.

12 In our previous study of meropenem-aggravated colonic GVHD, we found that mucus-13 degrading functionality of *B. theta* is repressed by higher concentrations of ambient monosaccharides, including especially xylose¹⁵. We thus quantified effects of *B. ovatus* on colonic 14 15 luminal concentrations of monosaccharides using ion chromatography-mass spectrometry (IC-16 MS). Interestingly, most monosaccharides were markedly increased in meropenem-treated mice 17 that received introduction of *B. ovatus* (Fig. 5b), indicating that *B. ovatus* may be raising 18 concentrations of monosaccharides by helping to degrade dietary-derived polysaccharides. To 19 evaluate if B. ovatus was sufficient to elevated monosaccharide concentrations by itself without 20 contributions from other intestinal bacteria, we utilized gnotobiotic mouse models. We measured 21 carbohydrate concentrations of colonic luminal contents collected from previously germ-free (GF) 22 mice two weeks after introduction of *B. ovatus*. We found increased concentrations of many 23 monosaccharides in the colonic lumen of mice monocolonized with *B. ovatus*, while GF mice had 24 very low concentrations of nearly all monosaccharides except ribose (Extended Data Fig. 4c). As

1	expected, monosaccharide concentrations in the colonic lumen of meropenem-untreated mice were
2	not significantly affected by <i>B. ovatus</i> introduction (Extended Data Fig. 4d). These results
3	suggested that <i>B. ovatus</i> functions in the setting of an injured microbiota to elevate concentrations
4	of monosaccharides in the colonic lumen. It has also been reported that B. ovatus can produce
5	indole-3-acetic acid and promote interleukin-22 production from immune cells, leading to
6	decreased colonic inflammation in a murine inflammatory bowel disease model ²⁵ . We did not
7	observe, however, significant changes in concentrations of tryptophan metabolites due to B. ovatus
8	in our model (Extended Data Fig. 4e). Thus, our results indicated that B. ovatus is effective in
9	elevating concentrations of monosaccharides in the colonic lumen of mice compared to mice with
10	an absent or injured microbiota.
11	
12	
13	Degradation of xylose-comprising polysaccharides by <i>B. ovatus</i> suppressed mucus-degrading
13 14	Degradation of xylose-comprising polysaccharides by <i>B. ovatus</i> suppressed mucus-degrading functionality by <i>B. theta</i>
14	functionality by <i>B. theta</i>
14 15	functionality by <i>B. theta</i> Interestingly, in contrast to <i>B. theta</i> , <i>B. ovatus</i> is known to have the ability to degrade
14 15 16	functionality by <i>B. theta</i> Interestingly, in contrast to <i>B. theta</i> , <i>B. ovatus</i> is known to have the ability to degrade xylose-comprising polysaccharides ^{16,26} . This led us to hypothesize that the ability of <i>B. ovatus</i> to
14 15 16 17	functionality by <i>B. theta</i> Interestingly, in contrast to <i>B. theta</i> , <i>B. ovatus</i> is known to have the ability to degrade xylose-comprising polysaccharides ^{16,26} . This led us to hypothesize that the ability of <i>B. ovatus</i> to degrade xylose-comprising polysaccharides could mediate GVHD. Because <i>B. ovatus</i> mediates
14 15 16 17 18	functionality by <i>B. theta</i> Interestingly, in contrast to <i>B. theta</i> , <i>B. ovatus</i> is known to have the ability to degrade xylose-comprising polysaccharides ^{16,26} . This led us to hypothesize that the ability of <i>B. ovatus</i> to degrade xylose-comprising polysaccharides could mediate GVHD. Because <i>B. ovatus</i> mediates effects on GVHD severity and on colonic monosaccharides only when introduced to mice
14 15 16 17 18 19	functionality by <i>B. theta</i> Interestingly, in contrast to <i>B. theta</i> , <i>B. ovatus</i> is known to have the ability to degrade xylose-comprising polysaccharides ^{16,26} . This led us to hypothesize that the ability of <i>B. ovatus</i> to degrade xylose-comprising polysaccharides could mediate GVHD. Because <i>B. ovatus</i> mediates effects on GVHD severity and on colonic monosaccharides only when introduced to mice following meropenem treatment, we quantified effects of meropenem-pretreatment on gene
14 15 16 17 18 19 20	functionality by <i>B. theta</i> Interestingly, in contrast to <i>B. theta</i> , <i>B. ovatus</i> is known to have the ability to degrade xylose-comprising polysaccharides ^{16,26} . This led us to hypothesize that the ability of <i>B. ovatus</i> to degrade xylose-comprising polysaccharides could mediate GVHD. Because <i>B. ovatus</i> mediates effects on GVHD severity and on colonic monosaccharides only when introduced to mice following meropenem treatment, we quantified effects of meropenem-pretreatment on gene expression of <i>B. ovatus</i> using microbial RNA sequencing of stool samples. We found that <i>B. ovatus</i>
14 15 16 17 18 19 20 21	functionality by <i>B. theta</i> Interestingly, in contrast to <i>B. theta</i> , <i>B. ovatus</i> is known to have the ability to degrade xylose-comprising polysaccharides ^{16,26} . This led us to hypothesize that the ability of <i>B. ovatus</i> to degrade xylose-comprising polysaccharides could mediate GVHD. Because <i>B. ovatus</i> mediates effects on GVHD severity and on colonic monosaccharides only when introduced to mice following meropenem treatment, we quantified effects of meropenem-pretreatment on gene expression of <i>B. ovatus</i> using microbial RNA sequencing of stool samples. We found that <i>B. ovatus</i> in meropenem-treated mice upregulated expression of PUL108, which contributes to degradation

1	Using network analysis, we investigated for potential interactions between gene expression
2	of B. ovatus and B. theta. Given our hypothesis that B. ovatus was performing metabolic functions
3	that inhibited B. theta utilization of mucins, we were particularly interested in PULs of B. ovatus
4	that were negatively associated with PULs of <i>B. theta</i> that were related to the degradation of mucin
5	O-glycans such as PULs 12, 14, 16, 72, 78, and 81 (Fig. 6a and Extended Data Fig. 5b).
6	Interestingly, one of the PULs of <i>B. theta</i> that participates in the degradation of mucin O-glycans,
7	PUL14, was negatively correlated with multiple PULs of <i>B. ovatus</i> including PUL73, -100, and -
8	108. Another PUL of <i>B. theta</i> that participates in the degradation of mucin O-glycans, PUL78, was
9	also negatively correlated with multiple PULs of <i>B. ovatus</i> including PUL42, -47, -73, -100, and -
10	108. Both PUL47 and PUL73 of B. ovatus have been reported to contribute the degradation of
11	xylose-comprising polysaccharides including xyloglucan, wheat arabinoxylan, oat spelt xylan, and
12	complex xylans ^{$26,27$} . This led us to ask if degradation of xylose-comprising polysaccharides by <i>B</i> .
13	ovatus could suppress mucin glycan utilization by B. theta in minimal media supplemented with
14	porcine gastric mucin. We evaluated the effects of combining this media with media conditioned
15	by <i>B. ovatus</i> for 48 hours in the presence of various polysaccharides (Fig. 6b). Interestingly, <i>B.</i>
16	ovatus culture media containing wheat arabinoxylan or tamarind xyloglucan each significantly
17	suppressed the growth as well as mucin degradation by <i>B. theta</i> , while <i>B. ovatus</i> culture medium
18	supplemented with starch, which is not composed of xylose, did not suppress the growth and mucin
19	degradation by B. theta (Fig. 6c). Finally, we asked what effects B. ovatus had on the gene
20	expression of <i>B. theta</i> . To evaluate this, we turned to gnotobiotic mice and evaluated fecal RNA
21	transcripts in germ-free mice 2 weeks after introducing either B. theta alone or B. ovatus as well
22	as B. theta. We found that introduction of B. ovatus resulted in B. theta significantly
23	downregulating PULs 12 and 73, both of which contribute to degradation of mucin O-glycans (Fig.
24	6d). Altogether, these data suggested that introduction of <i>B. ovatus</i> into meropenem-treated allo-

HSCT mice resulted in a carbohydrate-enriched intestinal environment in the colonic lumen by
 degrading dietary-derived polysaccharides such as xylose-comprising polysaccharides, leading to
 inhibition of *B. theta* mucin utilization, ultimately resulting in amelioration of disrupted
 microbiota-induced severe GVHD.

- 5
- 6

Discussion

Allo-HSCT is a curative therapy for high-risk hematological malignancies, but complications such as infections and GVHD continue to limit its success. The intestinal microbiota is an important modulator of GVHD, and broad-spectrum antibiotics are known to increase the incidence of aGI-GVHD by compromising several functions of an intact intestinal microbiota, resulting in alterations to the intestinal environment including reduced concentrations of metabolic products in the colonic lumen¹⁵. The poor prognosis of severe aGI-GVHD underlines the need to better understand how intestinal microbes can help suppress GVHD in allo-HSCT.

In this study, we investigated the impact of the intestinal microbiota on treatment 14 15 responsiveness of aGI-GVHD using clinical microbiome data. In our retrospective analysis of the 16 fecal microbiome in aGI-GVHD patients, we found that an altered microbiome profile at 17 presentation of aGI-GVHD and a history of treatment with carbapenem-class antibiotics such as 18 meropenem were significantly associated with developing steroid-refractory GVHD, whereas a 19 high abundance of the commensal species *B. ovatus*, commonly found in normal individuals, was 20 significantly associated with improved GVHD response to steroid therapy. Consistent with this 21 result, B. ovatus has previously been associated with reduced incidence of GVHD^{28} . However, it 22 has not been well studied whether *B. ovatus* can mechanistically suppress severe GVHD.

23 Some prior studies have reported that *B. ovatus* can mediate multiple beneficial functions 24 in maintaining intestinal homeostasis in the host via production of indole-3-acetic acid or

1	sphingolipid production ^{25,29} . Here, in a murine model, we found that introduction of <i>B. ovatus</i>
2	resulted in improved survival in meropenem-treated allo-HSCT mice but not in meropenem-
3	untreated allo-HSCT mice. This suggested that B. ovatus helped suppress GVHD only in hosts
4	with a disrupted microbiota, and that a key function of B. ovatus may be related to mechanisms
5	underlying aggravated colonic GVHD in the setting of antibiotic injury. Unlike B. ovatus, B. theta
6	is known to be capable of utilizing host-derived glycans ^{30,31} , and was found to aggravate colonic
7	GVHD in our prior study ¹⁵ . In this study, we found that in the setting of an antibiotic-disrupted
8	microbiota with expansion of mucus-degrading B. theta, the introduction of B. ovatus ameliorated
9	the severity of colonic GVHD via polysaccharide degradation, thus producing abundant
10	monosaccharides and improving the intestinal metabolomic environment in allo-HSCT.

11 As limitations, this clinical microbiome analyses were retrospectively performed with 12 relatively small numbers in our cohort. The timing of stool collection relative to allo-HSCT was 13 different in each patient, so the effects of antibiotic exposure during allo-HSCT and the impacts of microbiota disruption due to antibiotics were potentially different individually. Also, we found 14 15 that steroid-refractory patients showed significantly higher histological GVHD grades of the colon 16 than steroid-responsive patients did. This could mean that severe mucosal injury from GVHD may 17 in itself cause a dysbiotic microbiota and also be associated with higher likelihood of steroidresistance. 18

In order to better determine causality, we conducted a murine GVHD model combined with
in vitro assays and were able to confirm that *B. ovatus* ameliorated meropenem-aggravated colonic
GVHD via xylose-comprising polysaccharide degradation. However, *B. ovatus* has a broad ability
to evoke not only carbohydrate degradation but also production of tryptophan metabolites²⁵,
sphingolipids²⁹, and bile salt hydrolase ³² and secretion of fecal immunoglobulin A³³. In addition,
although we confirmed that *B. ovatus* could ameliorate GVHD caused by dysbiotic microbiota in

1 a murine model, we are still not sure whether *B. ovatus* is also associated with the efficacy of 2 steroid therapy for aGI-GVHD. Further studies will be needed to fully understand the influence 3 the intestinal microbiota plays with regard to response to therapy.

4 In summary, an antibiotic-disrupted microbiota caused by carbapenems including 5 meropenem increased the severity of intestinal GVHD and was associated with treatment-6 refractory aGI-GVHD in patients. Mouse modeling demonstrated that introducing *B. ovatus* can 7 ameliorate the severity of GVHD in a model of meropenem-aggravated colonic GVHD. This 8 understanding of how specific bacteria such as *B. ovatus* can reduce intestinal inflammation should 9 facilitate the development of new strategies to better prevent and treat this important limitation of 10 allo-HSCT.

11

12 Acknowledgments

13 We thank Micah Bhatti at The University of Texas MD Anderson Cancer Center for supporting human fecal sample collection in this work. We thank Eric Pamer at University of Chicago, Pavan 14 15 Reddy at Baylor College of Medicine, Takanori Teshima at Hokkaido University Faculty of 16 Medicine, and Alan Hanash at Memorial Sloan Kettering Cancer Center for serving as external 17 advisory committee members of this work. This work was supported by funding from National 18 Institutes of Health grant 2R01HL124112-06 and Cancer Prevention & Research Institute of Texas 19 RR160089 to R.R.J., National Institutes of Health Cancer Center Support (CORE) Grant 20 5P30CA016672-42 to P.L.L. and R.R.J., and ASTCT New Investigator Award to E.H. C.B.P. was 21 partially supported by NIH R01HL158796 and NIH/NCI CCSG P30CA016672 (Biostatistics 22 Resource Group). The manuscript was edited by Sarah Bronson of the Research Medical Library 23 at The University of Texas MD Anderson Cancer Center.

Author contributions

2	Conceptualization: E.H., R.S.M., A.M.A., R.R.J; methodology: E.H., T. Hayase, C.C., M.A.J.,
3	C.B.P., E.C.M., R.R.J.; investigation: E.H., R.S.M., T. Hayase, A.M., S.C.S, M.A.J., M.R.O.,
4	C.A.S., S.S.A., J.L.K., C.C., I.I.F., L.K.M., A.N.B., R.K.E., V.A.C., L.T., B.Q.T., D.P., T. Halsey,
5	Y.J., W.T., R.P., I.R., N.J.A., J.A.W., C.L., S.W.F., M.E.C., S.S., P.C.O., G.R., J.J.M., R.E.C.,
6	E.J.S., P.L.L., E.C.M., A.M.A.; visualization: E.H., T. Hayase; funding acquisition: E.H., P.L.L.,
7	R.R.J.; project administration: E.H., R.S.M., A.M.A, R.R.J.; supervision: T. Hayase, C.B.P.,
8	E.C.M., A.M.A., R.R.J.; writing – original draft: E.H.; writing – review & editing: A.M.A., R.R.J.
9	
10	Declaration of interests
11	R.R.J. has served as a consultant or advisory board member for Merck, Microbiome DX, Karius,
12	MaaT Pharma, LISCure, Seres, Kaleido, and Prolacta and has received patent license fee or stock
13	options from Seres and Kaleido. E.J.S. has served as a consultant or advisory board member for
14	Adaptimmune, Axio, Navan, Fibroblasts and FibroBiologics, NY Blood Center, and Celaid
15	Therapeutics and has received patent license fee from Takeda and Affimed. E.H., M.A.J., J.L.K.,
	Therapeutes and has received patent noense ree nom rakeau and rithined. Eith, in its, or Eith,
16	and R.R.J. are inventors on a patent application by The University of Texas MD Anderson Cancer
16 17	
	and R.R.J. are inventors on a patent application by The University of Texas MD Anderson Cancer





Fig. 1. The high abundance of *Bacteroides* was associated with steroid-responsive GVHD. (a) Cluster dendrogram analyzed using H-clustering of weighted UniFrac. (b) The microbiome composition shown as stacked bar graphs. (c) PCoA of fecal samples collected from healthy volunteers or each cluster of aGI-GVHD patients. (d) Distances from healthy volunteers in weighted UniFrac. (e) Numbers of patients with steroid-responsive and -refractory GVHD. (f) Proportions of patients with steroid-responsive and -refractory GVHD. (g) Volcano plot of differentially abundant genera between clusters 1 and 2.



2 Fig. 2. Steroid-refractory aGI-GVHD patients showed significantly dysbiotic intestinal 3 microbiome than steroid-responsive aGI-GVHD patients. (A-E) The intestinal microbiome 4 analyzed by 16S rRNA sequencing in patient stool samples collected at presentation with acute 5 intestinal graft-versus-host disease (aGI-GVHD). (A) Alpha diversity shown as Shannon index. 6 (B) Principal coordinates analysis (PCoA) of fecal samples collected from healthy volunteers or 7 steroid-responsive or steroid-refractory patients. (C) Distances from healthy volunteers in 8 weighted UniFrac. (D) Volcano plot of differentially abundant genera. (E) The composition of the 9 intestinal microbiome.

1





Fig. 3. The high abundance of Bacteroides ovatus and B. ovatus-derived pathways were associated with steroid-responsive GVHD. (A) Graphical summary of antibiotics used in individual patients. (B) Numbers of patients with antibiotic exposure between hematopoietic stem

cell transplant (HSCT) and the onset of GVHD. (C-F) Data analyzed by shotgun sequencing of
fecal samples collected from aGI-GVHD patients (steroid-responsive; n=11, steroid-refractory;
n=12). (C) Volcano plot of differentially abundant species between steroid-responsive and -
refractory GVHD. (D) PCoA of genes in the genus Bacteroides. (E) Volcano plot of differentially
abundant pathways of the genus Bacteroides. (F) The top 50 subclasses of differentially abundant
pathways of the genus Bacteroides.






3

4

5


Fig. 4. Bacteroides ovatus improved GVHD-related mortality in meropenem-aggravated colonic GVHD via suppressing the abundance of B. theta. (A) Experimental schema of murine GVHD model using meropenem treatment followed by oral gavage of 20 million colony-forming units of B. ovatus daily for 3 days. (B) Overall survival after allo-HSCT. Data are combined from 6 two independent experiments. (C) Bacterial densities of mouse stool samples collected on day 21 7 after administering meropenem by drinking water. Bacterial densities were measured by 16S 8 rRNA gene qPCR. (D) Alpha diversity, measured by the Shannon index, was quantified in fecal samples. (E) Bacterial genera composition of fecal samples. (F) Relative abundance of B. ovatus

1	(left) and <i>B. theta</i> (right). (G) Periodic acid-Schiff (PAS) staining of histological colon sections
2	collected on day 23. Bar, 100 μ m. The areas inside dotted lines indicate the inner dense colonic
3	mucus layer. (H) Mucus thickness on day 23. Data are shown from one representative experiment.
4	
5	



1 Fig. 5. Mucolytic activity of Bacteroides thetaiotaomicron is suppressed in meropenem-2 treated mice by administration of Bacteroides ovatus. (A) Heatmap showing scaled relative 3 expression levels of polysaccharide utilization loci (PULs) in B. theta RNA transcripts sequenced 4 from stool collected from meropenem-treated allo-HSCT mice with or without administration of 5 B. ovatus on day 21. Right: Significantly altered PULs and their substrates. (B) Relative 6 abundances of monosaccharides of supernatants from colonic luminal content collected from 7 meropenem-treated allo-HSCT mice with or without administration of B. ovatus on day 23 measured by ion chromatography-mass spectrometry (IC-MS). Combined data from two 8 9 independent experiments are shown as means \pm SEM.

Negative correlation networks between B. ovatus and B. thetaiotaomicron



1 2

3

4

Fig. 6. Degradation of xylose-comprising polysaccharides by *Bacteroides ovatus* suppressed mucus-degrading functionality by *Bacteroides thetaiotaomicron*. (a) The correlation network analysis of *B. ovatus* RNA transcripts and *B. theta* RNA transcripts sequenced from stool collected on day 21 from meropenem-treated and -untreated allogeneic mice with administration of *B.*

1 ovatus. Only negatively correlated networks are shown. (b) Experimental schema of in vitro 2 bacterial culture assay using B. ovatus (MDA-HVS BO001) cultured in minimum nutrition 3 medium with each polysaccharide and *B. theta* (MDA-JAX BT001) cultured in BYEM10 with 4 porcine gastric mucin. (c) Normalized concentrations of porcine gastric mucin in the culture 5 supernatant were determined using a PAS-based colorimetric assay. Combined data from two 6 independent experiments are shown as means \pm SEM. (d) Heatmap showing scaled relative 7 expression levels of polysaccharide utilization loci (PULs) in B. theta RNA transcripts sequenced 8 from stool collected from B. theta (ATCC 29148)-colonized gnotobiotic mice with or without co-9 administration of *B. ovatus*. Transcripts were evaluated on day 14 after bacterial introduction to 10 germ-free mice. Right: Significantly altered PULs and their substrates.

Supplemental information

	n = 37
Median age (range), y	55 (22-74)
Male, n (%)	26 (70%)
Donor type, n (%)	
MRD	11 (30%)
MUD	20 (54%)
Haplo	6 (16%)
Cell source, n (%)	
Bone marrow	4 (11%)
Peripheral blood	33 (89%)
Conditioning, n (%)	
Myeloablative	24 (65%)
Non-myeloablative	13 (35%)
GVHD prophylaxis, n (%)	
PTCy/Tacrolimus	8 (22%)
PTCy/Tacrolimus/MMF	8 (22%)
Tacrolimus/MTX	9 (24%)
Tacrolimus/MTX/ATG	5 (14%)
Tacrolimus/MMF	5 (14%)
Tacrolimus/MMF/ATG	2 (5%)
Median day of aGI-GVHD onset (range)	36 (13-367)
aGI-GVHD clinical stages, n (%)	
Stage 0-2	25 (68%)
Stage 3-4	11 (30%)
Unknown	1 (3%)
Histology grades of the colon, n (%)	、 /
Grade 0-2	28 (76%)
Grade 3-4	9 (24%)

Table S1. Patient characteristics of all allo-HSCT patients with aGI-GVHD.

5 ATG, anti-thymocyte globulin; GVHD, graft-versus-host disease; aGI-GVHD, acute

6 gastrointestinal GVHD; Haplo, human leukocyte antigen (HLA)-haploidentical related donor;

7 MRD, HLA-matched related donor; MTX, methotrexate; MMF, mycophenolate mofetil; MUD,

8 HLA-matched unrelated donor; PTCy, post-transplant cyclophosphamide.

Table S2.			
and	2	by	

	Cluster 1	Cluster 2	P value
	(n = 9)	(n = 28)	
Median age (range), y	60 (46-69)	51 (22-74)	0.05
Male, n (%)	7 (78%)	19 (66%)	0.01
Donor type, n (%)			0.9
MRD	3 (33%)	8 (28%)	
MUD	5 (56%)	15 (54%)	
Haplo	1 (11%)	5 (18%)	
Cell source, n (%)			1.0
Bone marrow	1 (11%)	3 (11%)	
Peripheral blood	8 (89%)	25 (89%)	
Conditioning, n (%)			1.0
Myeloablative	6 (66%)	18 (64%)	
Non-myeloablative	3 (33%)	10 (36%)	
GVHD prophylaxis, n (%)		(),	0.9
PTCy/Tacrolimus	2 (22%)	6 (21%)	
PTCy/Tacrolimus/MMF	3 (33%)	5 (18%)	
Tacrolimus/MTX	3 (33%)	6 (21%)	
Tacrolimus/MTX/ATG	0 (0%)	5 (18%)	
Tacrolimus/MMF	0 (0%)	5 (18%)	
Tacrolimus/MMF/ATG	1 (11%)	1 (3%)	
Median day of aGI-GVHD onset (range)	27 (14-127)	41 (13-367)	0.04
aGI-GVHD clinical stages, n (%)	× ,	× ,	0.8
Stage 0-2	7 (77%)	18 (64%)	
Stage 3-4	2 (22%)	9 (32%)	
Unknown	0 (0%)	1 (4%)	
Histology grades of the colon, n (%)	× /	~ /	0.4
Grade 0-2	8 (88%)	20 (71%)	
Grade 3-4	1 (11%)	8 (29%)	

 Table S2. Patient characteristics of allo-HSCT patients who were classified into clusters 1

 and 2 by intestinal microbiome profiling at the onset of aGI-GVHD.


Non-repeated ANOVA was used to compare continuous variables, while chi-square or Fisher
exact test was used to analyze the frequency distribution between categorical variables. *P*-value
under 0.05 was considered statistically significant. ATG, anti-thymocyte globulin; GVHD, graftversus-host disease; aGI-GVHD, acute gastrointestinal GVHD; Haplo, human leukocyte antigen
(HLA)-haploidentical related donor; MRD, HLA-matched related donor; MTX, methotrexate;
MMF, mycophenolate mofetil; MUD, HLA-matched unrelated donor; PTCy, post-transplant
cyclophosphamide.

1	
2	
3	


	Steroid-responsive	Steroid-refractory	P value
	(n = 20)	(n = 17)	
Median age (range), y	62 (46-74)	45 (22-71)	0.0001
Male, n (%)	11 (55%)	13 (77%)	0.3
Donor type, n (%)			0.6
MRD	5 (25%)	6 (35%)	
MUD	13 (65%)	7 (41%)	
Haplo	2 (10%)	4 (24%)	
Cell source, n (%)			1.0
Bone marrow	2 (10%)	2 (10%)	
Peripheral blood	18 (86%)	17 (85%)	
Conditioning, n (%)			0.7
Myeloablative	12 (60%)	12 (71%)	
Non-myeloablative	8 (40%)	5 (29%)	
GVHD prophylaxis, n (%)			0.5
PTCy/Tacrolimus	7 (35%)	1 (6%)	
PTCy/Tacrolimus/MMF	4 (20%)	4 (24%)	
Tacrolimus/MTX	4 (20%)	5 (29%)	
Tacrolimus/MTX/ATG	1 (5%)	4 (24%)	
Tacrolimus/MMF	2 (10%)	3 (18%)	
Tacrolimus/MMF/ATG	2 (10%)	0 (0%)	
Median day of aGI-GVHD onset (range)	32 (14-367)	42 (13-253)	0.13
aGI-GVHD clinical stages, n (%)		× /	0.03
Stage 1-2	18 (90%)	7 (41%)	
Stage 3-4	2 (10%)	9 (53%)	
Unknown	0 (0%)	1 (5%)	
Histology grades of the colon, n (%)	× /		0.005
Grade 0-2	19 (95%)	9 (53%)	
Grade 3-4	1 (5%)	8 (47%)	

Table S3. Patient characteristics of allo-HSCT patients who underwent intestinalmicrobiome profiling at the onset of aGI-GVHD.


Non-repeated ANOVA was used to compare continuous variables, while chi-square or Fisher
exact test was used to analyze the frequency distribution between categorical variables. *P*-value
under 0.05 was considered statistically significant. ATG, anti-thymocyte globulin; GVHD, graftversus-host disease; aGI-GVHD, acute gastrointestinal GVHD; Haplo, human leukocyte antigen
(HLA)-haploidentical related donor; MRD, HLA-matched related donor; MTX, methotrexate;
MMF, mycophenolate mofetil; MUD, HLA-matched unrelated donor; PTCy, post-transplant
cyclophosphamide.



Extended Data Fig. 1. aGI-GVHD patients showed a higher proportion of carbapenem
exposure. (A) PCoA of fecal samples collected from healthy volunteers or aGI-GVHD patients.
(B) Volcano plot of differentially abundant genera analyzed by 16S rRNA gene sequencing of
fecal samples compared between healthy volunteers and aGI-GVHD patients. (C) Relative
abundance of genera that were significantly different between steroid-responsive and -refractory
aGI-GVHD.




2 Extended Data Fig. 2. *Bacteroides ovatus* did not show mucus-degrading functionality like *B*. 3 theta. (A) Circular plot of open reading frames (ORFs) derived from the complete genome (MDA-4 HVS BO001). Blue and green bars represent ORFs on the plus strand and the minus strand, respectively. Inner purple-olive ring depicts degree of GC skewing. (B) Experimental schema of 5 6 in vitro bacterial culture assay of *B. theta* (MDA-JAX BT001) or *B. ovatus* (MDA-HVS BO001) 7 in media with porcine gastric mucin-containing medium. (C) Relative concentrations of porcine 8 gastric mucin in medium following culture with B. theta (MDA-JAX BT001) or B. ovatus (MDA-9 HVS BO001). B. theta or B. ovatus was first introduced to porcine gastric mucin-containing 10 medium. At 24 hours of culture, levels of mucin glycans in the culture supernatant were determined 11 using a colorimetric assay.



Extended Data Fig. 3. Introduction of Bacteroides ovatus did not alter abundance and 2 3 functionality of *B. theta* in meropenem-untreated allo-HSCT mice. (A) Experimental schema 4 of murine GVHD model with oral gavage of 20 million colony-forming units of *B. ovatus* daily 5 from days 16 to 18. (B) Overall survival after allo-HSCT. Data are combined from two independent experiments. (C) Bacterial densities of mouse stool samples collected on day 21. 6 7 Bacterial densities were measured by 16S rRNA gene qPCR. (D) Alpha diversity, measured by 8 the Shannon index, was quantified in fecal samples. (E) Bacterial genera composition of fecal 9 samples. (F) Relative abundance of B. ovatus (left) and B. theta (right). (B-F) Combined data from 10 two independent experiments. (G) PAS staining of histological colon sections collected on day 23.

- 1 Bar, 100 μm. The areas inside dotted lines indicate the inner dense colonic mucus layer. (H) Mucus
- 2 thickness on day 23. Data are shown from one representative experiment.







Extended Data Fig. 4. Introduction of *Bacteroides ovatus* increased fecal levels of soluble monosaccharides in mice monocolonized with *B. ovatus*. (A) Heatmap showing scaled relative

expression levels of polysaccharide utilization loci (PULs) in *B. theta* RNA transcripts sequenced
from stool collected from meropenem-treated allo-HSCT mice with or without administration of *B. ovatus* on day 21. Right: PULs and their modularity and substrate names. (B) Relative
expression levels of PULs in *B. theta* RNA transcripts sequenced from stool collected on day 21
from meropenem-untreated allo-HSCT mice with or without administration of *B. ovatus*. Right:
PULs and their modularity.

7 (C) Relative abundances of monosaccharides of supernatants from colonic luminal content 8 collected from germ-free (GF) mice with or without administration of B. ovatus on day 14 9 measured by IC-MS. Data are shown from one representative experiment. (**D**) Relative abundances 10 of monosaccharides of supernatants from colonic luminal content collected from meropenem-11 untreated allo-HSCT mice with or without administration of *B. ovatus* on day 23 measured by ion 12 chromatography-mass spectrometry (IC-MS). Data are shown from one representative experiment. 13 (E) Absolute abundances of tryptophan metabolites of supernatants from colonic luminal content collected from meropenem-treated allo-HSCT mice with or without administration of *B. ovatus* on 14 15 day 23 measured by liquid chromatography coupled with high-resolution mass spectrometry (LC-16 HRMS). Data are combined from two independent experiments and are shown as means \pm SEM.



b Negative correlation networks between *B. ovatus* and *B. thetaiotaomicron*



1

Extended Data Fig. 5. PULs of *Bacteroides ovatus* were significantly altered in meropenemtreated allo-HSCT mice compared to meropenem-untreated mice. (A) Relative expression levels of PULs in *B. ovatus* RNA transcripts sequenced from stool collected from allo-HSCT mice treated or untreated with meropenem on day 28. Right: PULs and their modularity and substrate names. (B) The correlation network analysis of *B. ovatus* RNA transcripts and *B. theta* RNA transcripts sequenced from stool collected on day 21 from meropenem-treated and -untreated allogeneic mice with administration of *B. ovatus*. Only negatively correlated networks are shown.

Methods

2 <u>Retrospective study design</u>

3 A total of 37 aGI-GVHD patients who underwent allo-HSCT during 2017 to 2019 at MD Anderson 4 Cancer Center provided stool samples for our biorepository, and these patient stool samples were 5 analyzed retrospectively. Acute GVHD was diagnosed by clinical and/or pathological findings and graded according to standard criteria³⁴. These patients included 28 with classic aGI-GVHD and 9 6 7 with late-onset aGI-GVHD by National Institutes of Health consensus criteria ¹⁷. We classified 8 patients by steroid responsiveness to GVHD, including 20 patients who were steroid-responsive 9 and 17 patients who were steroid-refractory. We determined treatment response as previously 10 reported ¹⁸: briefly, a lack of response on the basis of organ assessment after at least 3 days of 11 high-dose systemic glucocorticoid therapy; a lack of improvement after 7 days; or treatment failure 12 during steroid tapering or an inability to taper the dose to <0.5 mg/kg/day of methylprednisolone. 13 All patients received initial therapy with methylprednisolone or prednisone at 2 mg/kg/day 14 followed by tapering per institutional guidelines. Signed informed consent was provided by all 15 study participants including healthy volunteers, and this study was approved by The University of 16 Texas MD Anderson's Institutional Review Board.

17

18 <u>Human samples</u>

19 Samples were collected from patients undergoing allo-HSCT and healthy volunteers and stored at

- 20 4°C for 24-48 hours until aliquoted for long-term storage at -80°C.
- 21
- 22 <u>Mice</u>

Female C57BL/6J (B6: H-2^b) and B6D2F1 (H-2^{b/d}, CD45.2⁺) were purchased from The Jackson
 Laboratory (Bar Harbor, ME). Eight- to 12-week-old female C57BL/6 germ-free mice for murine

1	studies were provided by the gnotobiotic facility of Baylor College of Medicine (Houston, TX).
2	All animal experiments were performed under the Guide for the Care and Use of Laboratory
3	Animals Published by the National Institutes of Health and was approved by the Institutional
4	Animal Care and Use Committee. Experiments in this manuscript were performed in a non-blinded
5	fashion.
6	
7	Antibiotics administration
8	Meropenem was dissolved with phosphate buffer, pH 8.0, and given at a concentration of 0.625
9	g/L in drinking water from day 3 to day 15 after transplant.
10	
11	<u>HSCT</u>
12	Mice received transplants as previously described ³⁵ . In brief, after receiving myeloablative total-
13	body irradiation (11 Gray) delivered in 2 doses at 4-hour intervals, B6D2F1 (H-2 ^{b/d}) mice were
14	intravenously injected with 5×10^6 bone marrow cells and 5×10^6 splenocytes from allogeneic B6
15	(H-2 ^b) donors. Female mice that were 8 to 12 weeks old were allocated randomly to each
16	experimental group, ensuring the mean body weight in each group was similar. Total body
17	radiotherapy was performed using a Shepherd Mark I, Model 30, ¹³⁷ Cs irradiator. Mice were
18	maintained in specific pathogen-free (SPF) conditions and received normal chow (LabDiet
19	PicoLab Rodent Diet 20 5053, Lab Supply). Survival after HSCT was monitored daily, and the
20	degree of clinical GVHD was assessed weekly using an established scoring system ³⁶ .
21	
22	Histological and immunohistochemistry analysis
23	For evaluation of mucus thickness, colonic sections containing stool pellets were fixed in
24	methanol-Carnoy fixative composed of methanol (60%), chloroform (30%) and glacial acetic acid

1	(10%) and 5 μ m sections were made and stained with periodic acid-Schiff (PAS). Sections were
2	imaged using an Aperio AT2. Mucus thickness of the colonic sections was measured using eSlide
3	Manager Version 12.4.3.5008. Eight measurements per image were taken and averaged over the
4	entire usable colon surface.
5	
6	Sequencing of 16S rRNA gene amplicons
7	Fecal samples that were collected from patients and mice were weighed before DNA isolation. In
8	brief, genomic DNA was isolated using the QIAamp DNA mini kit (51306, Qiagen) according to
9	the manufacturer's protocol, which was modified to include an intensive bead-beating lysis step.
10	The V4 region of the 16S rRNA gene was amplified by PCR from 100 ng of extracted genomic
11	DNA using 515 forward and 806 reverse primer pairs ³⁷ . The quality and quantity of the barcoded
12	amplicons were assessed on an Agilent 4200 TapeStation system and Qubit Fluorometer (Thermo
13	Fisher Scientific), and libraries were prepared after pooling at equimolar ratios. The final libraries
14	were purified using QIAquick gel extraction kit (28706X4, Qiagen) and sequenced with a 2×250
15	base pair paired-end protocol on the Illumina MiSeq platform.
16	
17	Microbiome data analysis
18	Sequencing data from paired-end reads were de-multiplexed using QIIME 2 ³⁸ . Merging of paired-
19	end reads, dereplicating, and length filtering was performed using VSEARCH 2.17.1 ³⁹ . Following
20	de-noising and chimera calling using the unoise3 command ⁴⁰ , unique sequences were
21	taxonomically classified with mothur ⁴¹ using the Silva database ⁴² version 138. Weighted UniFrac
22	distances ⁴³ were determined using QIIME 2, visualized using PCoA, and evaluated for statistical
23	significance using PERMANOVA testing. For differential abundance analysis, abundances of
24	sequences belonging to taxonomical groups were included for analysis using DESeq2 and adjusted

for multiple comparisons using the method of Benjamini and Hochberg. Patient microbiome data were classified into 2 clusters using the heluster function by the amap library of R.

3

2

4 Quantification of fecal bacterial density

5 Genomic DNA was isolated from stool as described above. qPCR was performed as previously 6 described ⁴⁴. In brief, 16S rRNA gene sequences were amplified from total fecal DNA using the 7 primers (5'-AAACTCAAAKGAATTGACGG-3') 926F and 1062R (5'-8 CTCACRRCACGAGCTGAC-3'). Real-time PCR was carried out in 96-well optical plates on 9 OuantStudio Flex 6 RT-PCR (Thermo Fisher) and KAPA SYBR FAST Master Mix (Roche). The 10 PCR conditions included one initial denaturing step of 10 min at 95°C and 40 cycles of 95°C for 11 20 sec and 60°C for 1 min. Melting-curve analysis was performed after amplification. To 12 determine bacterial density, a plasmid with a 16S rRNA gene of a murine *Blautia* isolate was 13 generated in the pCR4 backbone and used as a standard.

14

15 <u>Culturing of bacteria</u>

16 Bacteroides ovatus (MDA-HVS BO001) was isolated and cultured from healthy volunteer's stool 17 samples in a Whitley anaerobic chamber (10% H₂, 5% CO₂ and 85% N₂). Human-derived *B. ovatus* (ATCC 8483) and human-derived *B. theta* (ATCC 29148) were purchased from American Type 18 19 Culture Collection (ATCC). Mouse-derived BT (MDA-JAX BT001) was previously isolated¹⁵. 20 Bacterial number was quantified using a Nexcelom Cellometer cell counter with SYTO BC dye 21 and propidium iodide. Bacterial growth experiments were performed in a liquid media, BYEM10, 22 composed of a hybrid of BHI and M10 supplemented with yeast extract as previously described ^{15,45}. Bacteria were cultured up to 24 or 48 hours at a starting concentration of 1×10^6 bacteria/ml 23 24 in BYEM10 broth (pH 7.2) with or without 5 mg/ml of porcine gastric mucin (M1778, SigmaAldrich), wheat arabionoxylan (wheat flour; low viscosity; Megazyme), xylan (Beechwood;
 Megazyme), xyloglucan (Tamarind; Megazyme), or starch (wheat; Sigma-Aldrich). Optical
 densities (OD_{600 nm}) of bacterial cultures were measured with a BioTek Epoch 2 plate reader.

4

5

Mucin degradation assay

6 Levels of mucin glycans in culture supernatants were determined by a PAS-based colorimetric 7 assay as previously described ^{15,45}. Briefly, culture supernatants were centrifuged at 20,000g for 8 10 minutes at 4°C and collected. To perform mucin precipitation, 500 µl of culture supernatants 9 was mixed with 1 ml of molecular grade ethanol and incubated at -30° C for overnight. Culture 10 supernatants were centrifuged at 20,000g for 10 minutes at 4°C. Mucin-containing pellets were 11 washed with 1 ml of molecular grade ethanol twice and resuspended in 500 µl of PBS. A total of 12 10 µl of washed culture supernatants was transferred into a round-bottom 96-well plate containing 13 15 µl of PBS. Serially diluted porcine gastric mucin (Sigma-Aldrich) standards were prepared. Freshly prepared 0.06% periodic acid in 7% acetic acid was added and incubated at 37°C for 90 14 15 min, followed by 100 µl of Schiff's reagent (84655, Sigma-Aldrich) and incubation at room 16 temperature for 40 min. Absorbance was measured at 550 nm using a BioTek Synergy HTX plate 17 reader.

18

19 <u>Analysis of carbohydrates by IC-MS</u>

To determine the relative abundance of carbohydrates in mouse fecal samples, extracts were prepared and analyzed by ultrahigh-resolution mass spectrometry. Fecal pellets were homogenized with a Precellys Tissue Homogenizer. Metabolites were extracted using 1 ml of ice-cold 80/20 (v/v) methanol/water. Extracts were centrifuged at 17,000g for 5 min at 4°C, and supernatants were transferred to clean tubes, followed by evaporation to dryness under nitrogen. Dried extracts

1	were reconstituted in deionized water, and 5 μl was injected for analysis by IC-MS. IC mobile
2	phase A (MPA; weak) was water, and mobile phase B (MPB; strong) was water containing 100
3	mM KOH. A Thermo Scientific Dionex ICS-5000+ system included a Thermo CarboPac PA20-
4	Fast column (4 μ m particle size, 100 × 2 mm) with the column compartment kept at 30°C. The
5	autosampler tray was chilled to 4°C. The mobile phase flow rate was 200 μ l/min, and the gradient
6	elution program was: 0-0.5 min, 1% MPB; 0.5-10 min, 1%-5% MPB; 10-15 min, 5%-95% MPB;
7	15-20 min, 95% MPB; 20.5-25, 95-1% MPB. The total run time was 25 min. To assist the
8	desolvation for better sensitivity, methanol was delivered by an external pump and combined with
9	the eluent via a low dead volume mixing tee. Data were acquired using a Thermo Orbitrap Fusion
10	Tribrid Mass Spectrometer under ESI negative ionization mode at a resolution of 240,000. Raw
11	data files were imported to Thermo TraceFinder and Compound Discoverer software for spectrum
12	database analysis. The relative abundance of each metabolite was normalized by sample weight.
13	
14	Analysis of tryptophan metabolites by LC-HRMS

15 To determine the relative concentration of tryptophan metabolites in mouse fecal samples, extracts 16 were prepared and analyzed by liquid chromatography coupled with high-resolution mass 17 spectrometry (LC-HRMS). Approximately 50 mg of stool was pulverized on liquid nitrogen, then 18 homogenized with Precellys Tissue Homogenizer. Metabolites were extracted using 0.5 ml of ice-19 cold 50/50 (v/v) methanol/acetonitrile followed by 0.5 mL 0.1% formic acid in 50/50 (v/v) 20 Acetonitrile/Water. Extracts were centrifuged at 17,000g for 5 min at 4°C, and supernatants were transferred to clean tubes, followed by evaporation to dryness under nitrogen. Samples were then 21 22 reconstituted in 50/50 (v/v) methanol/water, then 10 µl was injected into a Thermo Vanquish liquid 23 chromatography (LC) system containing a Waters XSelect HSS T3 2.1 × 150 mm column with 24 2.5-µm particle size. MPA was 0.1% formic acid in water. MPB was 100% methanol. The flow

rate was 200 µl/min (at 35°C), and the gradient conditions were: initial 5% MPB, increased to 95%
MPB at 15 min, held at 95% MPB for 5 min, and returned to initial conditions and equilibrated for
5 min. The total run time was 25 min. Data were acquired using a Thermo Orbitrap Fusion Tribrid
mass spectrometer under ESI positive and negative ionization modes at a resolution of 240,000
with full scan mode. Raw data files were imported into Thermo TraceFinder software for final
analysis. The relative concentration of each compound was normalized by stool weight.

- 7
- 8

Whole-genome sequencing of patient fecal samples

9 Genomic DNA was isolated from patient fecal samples and purified using a Oiagen Genomic-tip 10 20/G column, according to the manufacturer's instructions. For short-read Illumina sequencing, 11 libraries were constructed with a Nextera DNA Flex Library Prep Kit (Illumina), according to the 12 manufacturer's protocol. All libraries were quantified with a TapeStation and pooled in equal 13 molar ratios. The final libraries were sequenced with the NovaSeq 6000 platform (Illumina) to produce 2×150 bp paired-end reads, resulting in ~5 Gb per sample. In sequencing analysis, 14 15 sequence reads were filtered by their quality using the VSEARCH 2.17.1. The abundance of taxa, 16 microbial metabolic pathways, and gene expression was profiled by the HUMAnN3. Differential 17 expression profiles were analyzed by the DESeq2 package in R.

18

19 Whole-genome sequencing of *B. ovatus* (MDA-HVS BO001)

B. ovatus (MDA-HVS BO001) genomic DNA was isolated and purified using a Qiagen Genomictip 20/G column, according to the manufacturer's instructions. For short-read Illumina sequencing,
libraries were constructed with a Nextera DNA Flex Library Prep Kit (Illumina, San Diego, CA,
USA), according to the manufacturer's protocol. All libraries were quantified with a TapeStation
and pooled in equal molar ratios. The final libraries were sequenced with the NovaSeq 6000

1	platform (Illumina) to produce 2×150 bp paired-end reads, resulting in ~5 Gb per sample. For
2	long-read Nanopore sequencing, 500 ng of genomic DNA was used for library preparation using
3	the Rapid Sequencing Kit (SQK-RAD004, Oxford Nanopore Technologies). Libraries were loaded
4	into a FLO-MIN106 flow-cell for a 24-h sequencing run on a MinION sequencer platform (Oxford
5	Nanopore Technologies, Oxford, UK). Data acquisition and real-time base calling were carried
6	out by the MinKNOW software version 3.6.5. The fastq files were generated from basecalled
7	sequencing fast5 reads.
8	
9	Hybrid assembly and genome annotation of B. ovatus (MDA-HVS BO001)
10	To assemble the complete genome of <i>B. ovatus</i> , Flye version 2.8.2 46 was used with long reads
11	(Nanopore) and short reads (NovaSeq) combined using default settings. The similarities of the
12	genome of MDA-HVS BO001 to other reference genomes was calculated using blastn for B.
13	(ATCC 8483) ⁴⁷ . Open reading frames of <i>B. ovatus</i> (MDA-HVS BO001) were identified using
14	prokka ⁴⁸ . The genome of <i>B. ovatus</i> and open reading frames were depicted using DNA plotter
15	software ⁴⁹ .
16	
17	RNA sequencing and analysis
18	Approximately 30 mg of stool was freshly collected in 700 µl of ice-cold QIAzol containing 200
19	µl of 0.1-mm-diameter Zirconia Silica beads (11079101z, BioSpec). Samples were bead beaten
20	twice for 2 min with a 30-s interval recovery. Samples were then centrifuged at 12,000g for 1 min,
21	and the supernatant was collected for RNA isolation using the RNeasy mini kit (74104, Qiagen).
22	RNA was treated on column with DNase I (79254, Qiagen) to eliminate contaminating genomic
23	DNA. RNA quantity and quality were determined using an Agilent 4200 TapeStation system
24	(Agilent). A total of 250 ng of total RNA from mouse stools was used to construct libraries using

1	the Universal Prokaryotic RNA-Seq Library Preparation Kit (9367-32, Tecan) with Unique Dual
2	Indexes (S02480-FG, Tecan), following the manufacturer's protocol. The cDNA libraries were
3	sequenced on the Illumina NovaSeq 6000 system to produce 2 \times 150 bp paired-end reads.
4	Sequence data were demultiplexed using QIIME 2 38 and their qualities were checked using
5	VSEARCH 2.17.1 ³⁹ . Data were filtered and truncated by quality with VSEARCH default settings.
6	The total reads of mouse stool samples were 160896223 ± 93489752 (mean \pm standard deviation).
7	Sequences of ribosomal RNA were removed using BWA software against prokaryotic ribosomal
8	RNA sequences from prokaryotic RefSeq genomes ⁵⁰ . Sequences of interest were further identified
9	using diamond software version 0.9.24 ⁵¹ to align against PULs. Features with percentage identity
10	less than 80% were excluded. The total counts of bacterial isolated samples were 360932 ± 284308
11	and 966485 \pm 617495 in <i>B. ovatus</i> and <i>B. theta</i> , respectively (mean \pm standard deviation). Aligned
12	mRNA expression changes were calculated using the DESeq2 in R software version 4.1.2 via
13	RStudio version 2022.02.0 Build 443. P values < 0.05 were considered statistically significant.
14	
15	Network analysis using bacterial RNA transcripts
16	The expressions of PULs of <i>B. theta</i> and <i>B. ovatus</i> in meropenem-untreated and -treated mice that
17	received B. ovatus were standardized by relative abundances in each sample. PULs with average
18	expression rates of 1% or less in each group were excluded from the network analysis. Each data
19	set was logit transformed, and then r and p values were calculated by Pearson correlation analysis
20	between <i>B. theta</i> and <i>B. ovatus</i> PULs. <i>P</i> values were corrected by false discovery rate (FDR).
21	PUL combinations showing a corrected p -value of 0.05 or less with a negative r value were
22	depicted using Cytoscape ⁵² for <i>B. theta</i> PULs known to degrade mucin-O-glycan.
23	

24 <u>Statistical analysis</u>

1	Data were checked for normality and similar variances between groups, and Student t-tests were
2	used when appropriate. Mann-Whitney U tests were used to compare data between two groups
3	when the data did not follow a normal distribution. Kaplan-Meier curves were used to depict
4	survival probabilities, and the log-rank test was applied to compare survival curves. For clinical
5	data analysis, non-repeated ANOVA was used to compare continuous variables, while chi-square
6	or Fisher exact tests were used to analyze the frequency distribution between categorical variables.
7	Analyses were performed using R software version 4.1.2 and Prism version 9.0 (GraphPad
8	Software). P values < 0.05 were considered statistically significant.
9	

1		References
2	1	Westin, J. R. et al. Steroid-Refractory Acute GVHD: Predictors and Outcomes. Adv
3		Hematol 2011, 601953 (2011). https://doi.org:10.1155/2011/601953
4	2	MacMillan, M. L. et al. Response of 443 patients to steroids as primary therapy for acute
5		graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant
6		8, 387-394 (2002). https://doi.org:10.1053/bbmt.2002.v8.pm12171485
7	3	Jagasia, M. et al. Ruxolitinib for the treatment of steroid-refractory acute GVHD
8		(REACH1): a multicenter, open-label phase 2 trial. Blood 135, 1739-1749 (2020).
9		https://doi.org:10.1182/blood.2020004823
10	4	Zeiser, R. et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host
11		Disease. N Engl J Med 382 , 1800-1810 (2020). <u>https://doi.org:10.1056/NEJMoa1917635</u>
12	5	Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in
13		health and disease. Cell Res 30, 492-506 (2020). https://doi.org:10.1038/s41422-020-0332-
14		2
15	6	Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota
16		and the immune system. <i>Science</i> 336 , 1268-1273 (2012).
17		https://doi.org:10.1126/science.1223490
18	7	Peled, J. U. et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell
19		Transplantation. N Engl J Med 382, 822-834 (2020).
20		https://doi.org:10.1056/NEJMoa1900623
21	8	Shono, Y. et al. Increased GVHD-related mortality with broad-spectrum antibiotic use
22		after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci
23		Transl Med 8, 339ra371 (2016). https://doi.org:10.1126/scitranslmed.aaf2311

- Hidaka, D. *et al.* The association between the incidence of intestinal graft-vs-host disease
 and antibiotic use after allogeneic hematopoietic stem cell transplantation. *Clin Transplant* 32, e13361 (2018). <u>https://doi.org:10.1111/ctr.13361</u>
- Farowski, F. *et al.* Impact of choice, timing, sequence and combination of broad-spectrum
 antibiotics on the outcome of allogeneic haematopoietic stem cell transplantation. *Bone Marrow Transplant* 53, 52-57 (2018). <u>https://doi.org:10.1038/bmt.2017.203</u>
- Lee, S. E. *et al.* Alteration of the Intestinal Microbiota by Broad-Spectrum Antibiotic Use
 Correlates with the Occurrence of Intestinal Graft-versus-Host Disease. *Biol Blood Marrow Transplant* 25, 1933-1943 (2019). <u>https://doi.org:10.1016/j.bbmt.2019.06.001</u>
- 12 Kakihana, K. *et al.* Fecal microbiota transplantation for patients with steroid-resistant acute
 graft-versus-host disease of the gut. *Blood* 128, 2083-2088 (2016).
 https://doi.org:10.1182/blood-2016-05-717652
- 1313Spindelboeck, W. *et al.* Repeated fecal microbiota transplantations attenuate diarrhea and14lead to sustained changes in the fecal microbiota in acute, refractory gastrointestinal graft-15versus-host-disease.Haematologica16https://doi.org:10.3324/haematol.2016.154351
- 17 14 van Lier, Y. F. *et al.* Donor fecal microbiota transplantation ameliorates intestinal graft 18 versus-host disease in allogeneic hematopoietic cell transplant recipients. *Sci Transl Med* 19 12 (2020). <u>https://doi.org:10.1126/scitranslmed.aaz8926</u>
- Hayase, E. *et al.* Mucus-degrading Bacteroides link carbapenems to aggravated graft versus-host disease. *Cell* 185, 3705-3719 e3714 (2022).
 <u>https://doi.org:10.1016/j.cell.2022.09.007</u>

- Desai, M. S. *et al.* A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus
 Barrier and Enhances Pathogen Susceptibility. *Cell* 167, 1339-1353 e1321 (2016).
 https://doi.org:10.1016/j.cell.2016.10.043
- Jagasia, M. H. *et al.* National Institutes of Health Consensus Development Project on
 Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis
 and Staging Working Group report. *Biol Blood Marrow Transplant* 21, 389-401 e381
 (2015). https://doi.org:10.1016/j.bbmt.2014.12.001
- 8 18 Harris, A. C. *et al.* International, Multicenter Standardization of Acute Graft-versus-Host
 9 Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD
 10 International Consortium. *Biol Blood Marrow Transplant* 22, 4-10 (2016).
 11 https://doi.org:10.1016/j.bbmt.2015.09.001
- 12 19 Eriguchi, Y. *et al.* Graft-versus-host disease disrupts intestinal microbial ecology by
 inhibiting Paneth cell production of alpha-defensins. *Blood* 120, 223-231 (2012).
 https://doi.org:10.1182/blood-2011-12-401166
- Stein-Thoeringer, C. K. *et al.* Lactose drives Enterococcus expansion to promote graft versus-host disease. *Science* 366, 1143-1149 (2019).
 https://doi.org:10.1126/science.aax3760
- Zocco, M. A., Ainora, M. E., Gasbarrini, G. & Gasbarrini, A. Bacteroides thetaiotaomicron
 in the gut: molecular aspects of their interaction. *Dig Liver Dis* 39, 707-712 (2007).
 https://doi.org:10.1016/j.dld.2007.04.003
- 21 22 Heimesaat, M. M. *et al.* MyD88/TLR9 mediated immunopathology and gut microbiota
 22 dynamics in a novel murine model of intestinal graft-versus-host disease. *Gut* 59, 1079 23 1087 (2010). https://doi.org:10.1136/gut.2009.197434

- Sofi, M. H. *et al.* A single strain of Bacteroides fragilis protects gut integrity and reduces
 GVHD. *JCI Insight* 6 (2021). https://doi.org:10.1172/jci.insight.136841
- 3 24 Terrapon, N. *et al.* PULDB: the expanded database of Polysaccharide Utilization Loci.
 4 *Nucleic Acids Res* 46, D677-D683 (2018). <u>https://doi.org:10.1093/nar/gkx1022</u>
- Ihekweazu, F. D. *et al.* Bacteroides ovatus Promotes IL-22 Production and Reduces
 Trinitrobenzene Sulfonic Acid-Driven Colonic Inflammation. *Am J Pathol* 191, 704-719
 (2021). https://doi.org:10.1016/j.ajpath.2021.01.009
- 8 26 Rogowski, A. *et al.* Glycan complexity dictates microbial resource allocation in the large
 9 intestine. *Nat Commun* 6, 7481 (2015). <u>https://doi.org:10.1038/ncomms8481</u>
- Martens, E. C. *et al.* Recognition and degradation of plant cell wall polysaccharides by two
 human gut symbionts. *PLoS Biol* 9, e1001221 (2011).
 https://doi.org:10.1371/journal.pbio.1001221
- 1328Golob, J. L. *et al.* Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute14Graft vs Host Disease After Hematopoietic Cell Transplantation. *Clin Infect Dis* 65, 1984-
- 15 1991 (2017). <u>https://doi.org:10.1093/cid/cix699</u>
- Brown, E. M. *et al.* Bacteroides-Derived Sphingolipids Are Critical for Maintaining
 Intestinal Homeostasis and Symbiosis. *Cell Host Microbe* 25, 668-680 e667 (2019).
 https://doi.org:10.1016/j.chom.2019.04.002
- Bergstrom, K. S. & Xia, L. Mucin-type O-glycans and their roles in intestinal homeostasis.
 Glycobiology 23, 1026-1037 (2013). https://doi.org:10.1093/glycob/cwt045
- 21 31 Tailford, L. E., Crost, E. H., Kavanaugh, D. & Juge, N. Mucin glycan foraging in the human
 22 gut microbiome. *Front Genet* 6, 81 (2015). <u>https://doi.org:10.3389/fgene.2015.00081</u>

- Yoon, S. *et al.* Bile salt hydrolase-mediated inhibitory effect of Bacteroides ovatus on
 growth of Clostridium difficile. *J Microbiol* 55, 892-899 (2017).
 https://doi.org:10.1007/s12275-017-7340-4
- Yang, C. *et al.* Fecal IgA Levels Are Determined by Strain-Level Differences in
 Bacteroides ovatus and Are Modifiable by Gut Microbiota Manipulation. *Cell Host Microbe* 27, 467-475 e466 (2020). <u>https://doi.org:10.1016/j.chom.2020.01.016</u>
- 7 34 Przepiorka, D. *et al.* 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow* 8 *Transplant* 15, 825-828 (1995).
- 9 35 Hayase, E. *et al.* R-Spondin1 expands Paneth cells and prevents dysbiosis induced by graft10 versus-host disease. J Exp Med 214, 3507-3518 (2017).
 11 https://doi.org:10.1084/jem.20170418
- 12 36 Cooke, K. R. *et al.* An experimental model of idiopathic pneumonia syndrome after bone
 marrow transplantation: I. The roles of minor H antigens and endotoxin. *Blood* 88, 3230 14 3239 (1996).
- 15 37 Caporaso, J. G. *et al.* Ultra-high-throughput microbial community analysis on the Illumina
 16 HiSeq and MiSeq platforms. *ISME J* 6, 1621-1624 (2012).
 17 https://doi.org:10.1038/ismej.2012.8
- Bolyen, E. *et al.* Reproducible, interactive, scalable and extensible microbiome data
 science using QIIME 2. *Nat Biotechnol* 37, 852-857 (2019).
 https://doi.org:10.1038/s41587-019-0209-9
- 21 39 Rognes, T., Flouri, T., Nichols, B., Quince, C. & Mahe, F. VSEARCH: a versatile open
 22 source tool for metagenomics. *PeerJ* 4, e2584 (2016). https://doi.org:10.7717/peerj.2584
- 23 40 Edgar, R. C. UNOISE2: improved error-correction for Illumina 16S and ITS amplicon
 24 sequencing. *bioRxiv*, 081257 (2016). https://doi.org:10.1101/081257

- Schloss, P. D. *et al.* Introducing mothur: open-source, platform-independent, community supported software for describing and comparing microbial communities. *Appl Environ Microbiol* 75, 7537-7541 (2009). <u>https://doi.org:10.1128/AEM.01541-09</u>
- 4 42 Quast, C. *et al.* The SILVA ribosomal RNA gene database project: improved data
 5 processing and web-based tools. *Nucleic Acids Res* 41, D590-596 (2013).
 6 https://doi.org:10.1093/nar/gks1219
- 43 Lozupone, C., Lladser, M. E., Knights, D., Stombaugh, J. & Knight, R. UniFrac: an
 effective distance metric for microbial community comparison. *ISME J* 5, 169-172 (2011).
 https://doi.org:10.1038/ismej.2010.133
- Yang, Y. W. *et al.* Use of 16S rRNA Gene-Targeted Group-Specific Primers for Real-Time
 PCR Analysis of Predominant Bacteria in Mouse Feces. *Appl Environ Microbiol* 81, 6749 6756 (2015). <u>https://doi.org:10.1128/AEM.01906-15</u>
- Schwabkey, Z. I. *et al.* Diet-derived metabolites and mucus link the gut microbiome to
 fever after cytotoxic cancer treatment. *Sci Transl Med* 14, eabo3445 (2022).
 https://doi.org:10.1126/scitranslmed.abo3445
- Kolmogorov, M., Yuan, J., Lin, Y. & Pevzner, P. A. Assembly of long, error-prone reads
 using repeat graphs. *Nat Biotechnol* 37, 540-546 (2019). <u>https://doi.org:10.1038/s41587-</u>
 019-0072-8
- Altschul, S. F., Gish, W., Miller, W., Myers, E. W. & Lipman, D. J. Basic local alignment
 search tool. *J Mol Biol* 215, 403-410 (1990). <u>https://doi.org:10.1016/S0022-</u>
 2836(05)80360-2
- 48 Seemann, T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30, 2068-2069
 (2014). <u>https://doi.org:10.1093/bioinformatics/btu153</u>

1	49	Carver, T., Thomson, N., Bleasby, A., Berriman, M. & Parkhill, J. DNAPlotter: circular
2		and linear interactive genome visualization. Bioinformatics 25, 119-120 (2009).
3		https://doi.org:10.1093/bioinformatics/btn578
4	50	Tatusova, T. et al. NCBI prokaryotic genome annotation pipeline. Nucleic Acids Res 44,
5		6614-6624 (2016). https://doi.org:10.1093/nar/gkw569
6	51	Buchfink, B., Xie, C. & Huson, D. H. Fast and sensitive protein alignment using
7		DIAMOND. Nat Methods 12, 59-60 (2015). https://doi.org:10.1038/nmeth.3176
8	52	Shannon, P. et al. Cytoscape: a software environment for integrated models of
9		biomolecular interaction networks. Genome Res 13, 2498-2504 (2003).
10		https://doi.org:10.1101/gr.1239303